GE HealthCare (GEHC) 10-Q 25 Jul 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Jul. 18, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		454,838,213
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31

Condensed Consolidated and Comb

Condensed Consolidated and Combined Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue	$ 4,817	$ 4,484	$ 9,524	$ 8,827
Gross profit	1,940	1,796	3,831	3,474
Selling, general, and administrative	1,072	908	2,134	1,839
Research and development	298	257	568	495
Total operating expenses	1,370	1,165	2,702	2,334
Operating income (loss)	570	631	1,129	1,140
Interest and other financial charges – net	137	12	273	16
Non-operating benefit (income) costs	(123)	(1)	(238)	(3)
Other (income) expense – net	(14)	(19)	(22)	(45)
Income from continuing operations before income taxes	570	639	1,116	1,172
Benefit (provision) for income taxes	(137)	(153)	(300)	(284)
Net income from continuing operations	433	486	816	888
Income from discontinued operations, net of taxes	0	12	0	12
Net income	433	498	816	900
Net (income) attributable to noncontrolling interests	(15)	(13)	(26)	(26)
Net income attributable to GE HealthCare	418	485	790	874
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	(183)	0
Net income attributable to GE HealthCare common stockholders	$ 418	$ 485	$ 607	$ 874
Earnings per share from continuing operations:
Basic (in dollars per share)	$ 0.92	$ 1.04	$ 1.34	$ 1.90
Diluted (in dollars per share)	0.91	1.04	1.33	1.90
Earnings per share attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	0.92	1.07	1.34	1.93
Diluted (in dollars per share)	$ 0.91	$ 1.07	$ 1.33	$ 1.93
Weighted-average number of shares outstanding:
Basic (in shares)	455	454	455	454
Diluted (in shares)	458	454	458	454
Products
Revenue	$ 3,213	$ 2,903	$ 6,344	$ 5,690
Cost of revenue	2,084	1,915	4,121	3,829
Services
Revenue	1,604	1,581	3,180	3,137
Cost of revenue	$ 793	$ 773	$ 1,572	$ 1,524

Condensed Consolidated and Co_2

Condensed Consolidated and Combined Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 418	$ 485	$ 790	$ 874
Net (income) attributable to noncontrolling interests	15	13	26	26
Net income	433	498	816	900
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	3	(472)	60	(625)
Benefit plans – net of taxes	(18)	3	(83)	(2)
Cash flow hedges – net of taxes	10	(9)	(29)	15
Other comprehensive income (loss)	(5)	(478)	(52)	(612)
Comprehensive income	428	20	764	288
Comprehensive (income) attributable to noncontrolling interests	(15)	(13)	(26)	(26)
Comprehensive income attributable to GE HealthCare	$ 413	$ 7	$ 738	$ 262

Condensed Consolidated and Co_3

Condensed Consolidated and Combined Statements of Financial Position (Unaudited) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Cash, cash equivalents, and restricted cash	$ 1,939	$ 1,445
Inventories	2,264	2,155
Contract and other deferred assets	1,044	989
All other current assets	596	417
Current assets	9,240	8,318
Property, plant, and equipment – net	2,357	2,314
Goodwill	12,929	12,813
Other intangible assets – net	1,423	1,520
Deferred income taxes	4,349	1,550
All other assets	2,013	1,024
Total assets	32,311	27,539
Short-term borrowings	5	15
Accounts payable	2,835	2,944
Contract liabilities	2,003	1,896
Current liabilities	7,581	7,191
Long-term borrowings	10,233	8,234
Compensation and benefits	5,167	549
Deferred income taxes	81	370
All other liabilities	1,926	1,603
Total liabilities	24,988	17,947
Commitments and contingencies
Redeemable noncontrolling interests	209	230
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 454,808,732 shares issued and outstanding as of June 30, 2023; 100 shares issued and outstanding as of December 31, 2022	5	0
Additional paid-in capital	6,451	0
Retained earnings	576	0
Net parent investment	0	11,235
Accumulated other comprehensive income (loss) – net	70	(1,878)
Total equity attributable to GE HealthCare	7,102	9,357
Noncontrolling interests	12	5
Total equity	7,114	9,362
Total liabilities, redeemable noncontrolling interests, and equity	32,311	27,539
Nonrelated party
Receivables, net	3,370	3,295
All other current liabilities	2,570	2,190
Related party
Statement of Financial Position [Abstract]
All other assets	88
All other liabilities	132
Receivables, net	27	17
All other current liabilities	$ 168	$ 146

Condensed Consolidated and Co_4

Condensed Consolidated and Combined Statements of Financial Position (Unaudited) (Parentheticals) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 92	$ 91
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	454,808,732	100
Common stock, outstanding (in shares)	454,808,732	100

Condensed Consolidated and Co_5

Condensed Consolidated and Combined Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Retained earnings	Net parent investment	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2021		0
Equity, beginning balance at Dec. 31, 2021	$ 16,676	$ 0	$ 0	$ 0	$ 17,692	$ (1,037)	$ 21
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to GE HealthCare	874				874
Currency translation adjustments – net of taxes	(625)					(625)
Benefit plans – net of taxes	(2)					(2)
Cash flow hedges – net of taxes	15					15
Transfers (to) from GE	114				114
Changes in equity attributable to noncontrolling interests	2						2
Equity, ending balance (in shares) at Jun. 30, 2022		0
Equity, ending balance at Jun. 30, 2022	17,054	$ 0	0	0	18,680	(1,649)	23
Equity, beginning balance (in shares) at Mar. 31, 2022		0
Equity, beginning balance at Mar. 31, 2022	16,578	$ 0	0	0	17,728	(1,171)	21
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to GE HealthCare	485				485
Currency translation adjustments – net of taxes	(472)					(472)
Benefit plans – net of taxes	3					3
Cash flow hedges – net of taxes	(9)					(9)
Transfers (to) from GE	467				467
Changes in equity attributable to noncontrolling interests	2						2
Equity, ending balance (in shares) at Jun. 30, 2022		0
Equity, ending balance at Jun. 30, 2022	$ 17,054	$ 0	0	0	18,680	(1,649)	23
Equity, beginning balance (in shares) at Dec. 31, 2022	100	0
Equity, beginning balance at Dec. 31, 2022	$ 9,362	$ 0	0	0	11,235	(1,878)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from Parent, including Spin-Off-related adjustments	(2,840)				(4,842)	2,000	2
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (in shares)		454,000,000
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0	$ 5	6,388		(6,393)
Issuance of common stock in connection with employee stock plans (in shares)		1,000,000
Issuance of common stock in connection with employee stock plans	11		11
Net income attributable to GE HealthCare	790			790
Dividends declared	(27)			(27)
Currency translation adjustments – net of taxes	60					60
Benefit plans – net of taxes	(83)					(83)
Cash flow hedges – net of taxes	(29)					(29)
Changes in equity attributable to noncontrolling interests	5						5
Share-based compensation expense	52		52
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	$ (187)			(187)
Equity, ending balance (in shares) at Jun. 30, 2023	454,808,732	455,000,000
Equity, ending balance at Jun. 30, 2023	$ 7,114	$ 5	6,451	576	0	70	12
Equity, beginning balance (in shares) at Mar. 31, 2023		455,000,000
Equity, beginning balance at Mar. 31, 2023	6,696	$ 5	6,425	185	0	75	6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from Parent, including Spin-Off-related adjustments	(6)				(9)		3
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0		(9)		9
Issuance of common stock in connection with employee stock plans	7		7
Net income attributable to GE HealthCare	418			418
Dividends declared	(27)			(27)
Currency translation adjustments – net of taxes	3					3
Benefit plans – net of taxes	(18)					(18)
Cash flow hedges – net of taxes	10					10
Changes in equity attributable to noncontrolling interests	3						3
Share-based compensation expense	$ 28		28
Equity, ending balance (in shares) at Jun. 30, 2023	454,808,732	455,000,000
Equity, ending balance at Jun. 30, 2023	$ 7,114	$ 5	$ 6,451	$ 576	$ 0	$ 70	$ 12

Condensed Consolidated and Co_6

Condensed Consolidated and Combined Statements of Changes in Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share)	$ 0.06	$ 0.06

Condensed Consolidated and Co_7

Condensed Consolidated and Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows - operating activities
Net income	$ 816	$ 900
Income from discontinued operations, net of taxes	0	12
Net income from continuing operations	816	888
Adjustments to reconcile Net income to Cash from (used for) operating activities
Depreciation and amortization of property, plant, and equipment	124	112
Amortization of intangible assets	189	204
Gain on fair value remeasurement of contingent consideration	(3)	0
Net periodic postretirement benefit plan (income) expense	(207)	6
Postretirement plan contributions	(180)	(12)
Provision for income taxes	300	284
Share-based compensation	52	39
Cash paid during the year for income taxes	(271)	(443)
Cash paid during the year for interest	(250)	0
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Receivables	(32)	(161)
Due from related parties	10	(1)
Inventories	(172)	(447)
Contract and other deferred assets	(64)	(96)
Accounts payable	(40)	282
Due to related parties	(11)	(48)
Contract liabilities	111	84
All other operating activities	29	(242)
Cash from (used for) operating activities – continuing operations	401	449
Cash flows – investing activities
Additions to property, plant, and equipment	(213)	(159)
Dispositions of property, plant, and equipment	1	3
Purchases of businesses, net of cash acquired	(147)	0
All other investing activities	9	(29)
Cash from (used for) investing activities – continuing operations	(350)	(185)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	(12)	0
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	2,000	0
Repayments and other reductions (maturities longer than 90 days)	(6)	(1)
Dividends paid to shareholders	(14)	0
Redemption of noncontrolling interests	(211)	0
Net transfers (to) from GE	(1,317)	(225)
All other financing activities	6	(54)
Cash from (used for) financing activities – continuing operations	446	(280)
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	(3)	(15)
Increase (decrease) in cash, cash equivalents, and restricted cash	494	(31)
Cash, cash equivalents, and restricted cash at beginning of year	1,451	561
Cash, cash equivalents, and restricted cash as of June 30	$ 1,945	$ 530

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION BACKGROUND. GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” or “we”) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. We operate at the center of the healthcare ecosystem, helping enable precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring. On January 3, 2023 (the “Distribution Date”), the General Electric Company (“GE” or “Parent”) completed the previously announced spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE's common stock as of the close of business on December 16, 2022 (the “Distribution”), which resulted in the issuance of approximately 454 million shares of common stock. Prior to the Distribution, the Company issued 100 shares of common stock in exchange for $1.00, all of which were held by GE as of December 31, 2022. As a result of the Distribution, the Company became an independent public company. Our common stock is listed under the symbol “GEHC” on the Nasdaq Stock Market LLC (“Nasdaq”). In the quarter ended June 30, 2023, GE disposed of approximately 29 million shares of its retained interest in GE HealthCare, reducing its beneficial ownership to approximately 13.5% of the Company’s outstanding common stock. In connection with the Spin-Off, certain adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,840 million. These items substantially consisted of the transfer of: (a) certain pension plan liabilities and assets as des cribed in Note 9, “Postretirement Benefit Plans,” (b) certain deferred income taxes as described in Note 10, “Income Taxes,” (c) deferred compensation liabilities of $548 million, and (d) employee termination obligations as described in Note 14, “Restructuring and Other Activities – Net.” In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. See Note 18, “Related Parties” for more information on these agreemen ts. Unless the context otherwise requires, references to “GE HealthCare,” “we,” “us,” “our,” and the “Company” refer to (i) GE’s healthcare business prior to the Spin-Off as a carve-out business of GE with related condensed combined financial statements and (ii) GE HealthCare Technologies Inc. and its subsidiaries following the Spin-Off with related condensed consolidated financial statements. BASIS OF PRESENTATION. The condensed consolidated and combined financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations and comprehensive income for the three and six months ended June 30, 2023 and 2022, cash flows for the six months ended June 30, 2023 and 2022, and the financial position as of June 30, 2023 and December 31, 2022. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S dollars (“USD”) unless otherwise stated. All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated and combined financial statements. These financial statements include certain transactions with GE, which are disclosed as related party transactions. See Note 18, “Related Parties” for further information. Prior to the Spin-Off, the condensed combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The condensed combined financial statements do not purport to reflect what the results of operations, comprehensive income, financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity during the periods presented. The condensed consolidated and combined financial statements should be read in conjunction with the Company’s audited combined financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022. ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. There have been no material impacts to our accounting estimates as of June 30, 2023 and December 31, 2022, or the results for the three and six months ended June 30, 2023 and 2022, from the COVID-19 pandemic. The federal COVID-19 Public Health Emergency declaration in the U.S. ended in May 2023, and COVID-19 restrictions have been lifted in many locations globally. We do not expect future material economic consequences from the COVID-19 pandemic . ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes , provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the condensed consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest wa s previously presented within “Interest and other financial charges – net” and has changed to being presented within “Benefit (provision) for income taxes.” The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements reflected in the Condensed Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50) . The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 17, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers

REVENUE RECOGNITION

REVENUE RECOGNITION	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITIONOur revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services. Contract and Other Deferred Assets As of June 30, 2023 December 31, 2022 Contract assets $ 642 $ 584 Other deferred assets 402 405 Contract and other deferred assets 1,044 989 Non-current contract assets (a) 54 37 Non-current other deferred assets (a) 84 82 Total contract and other deferred assets $ 1,182 $ 1,108 (a) Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position. Contract assets primarily reflect revenue recognized on contracts in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs. CONTRACT LIABILITIES. Contract liabilities primarily include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which remaining performance obligations are expected to be satisfied and fulfilled with our customers. As of June 30, 2023 and December 31, 2022, contract liabilities were approximately $2,673 million and $2,526 million, respectively, of which the non-current portion of $670 million and $630 million, respectively, was recognized in All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position. Contract liabilities increased by $147 million in 2023 primarily due to an increase in customer advances and deposits as a result of product orders growth relative to fulfillment and the normal annual service contract billing cycle. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,105 million and $1,083 million for the six months ended June 30, 2023 and 2022, respectively. REMAINING PERFORMANCE OBLIGATIONS. Remaining performance obligations represent the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty. As of June 30, 2023, the aggregate amount of the contracted revenues allocated to our unsatisfied (or partially unsatisfied) performance obligations was $14,309 million. We expect to recognize revenue as we satisfy our remaining performance obligations as follows: a) product-related remaining performance obligations of $4,992 million of which 99% is expected to be recognized within two years, and the remaining thereafter; and b) services-related remaining performance obligations of $9,317 million of which 67% and 97% is expected to be recognized within two years and five years, respectively, and the remaining thereafter.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in the “Business” section of our Annual Report on Form 10-K for the year ended December 31, 2022. The performance of these segments is principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as Income from continuing operations before income taxes in our Condensed Consolidated and Combined Statements of Income less the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gains and losses of business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gains and losses. Total Revenues by Segment For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Imaging: Radiology $ 2,227 $ 2,064 $ 4,315 $ 3,982 Interventional Guidance 393 385 801 778 Total Imaging 2,620 2,449 5,116 4,760 Total Ultrasound 839 828 1,698 1,643 PCS: Monitoring Solutions 563 512 1,115 1,033 Life Support Solutions 207 201 436 396 Total PCS 770 713 1,551 1,429 Total PDx 568 478 1,126 962 Other (a) 20 16 33 33 Total revenues $ 4,817 $ 4,484 $ 9,524 $ 8,827 (a) Financial information not presented within the reportable segments, shown within the Other category, represents the Hea lthCar e Financial Services (“HFS”) business which does not meet the definition of an operating segment. Segment EBIT For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Segment EBIT Imaging $ 278 $ 306 $ 469 $ 512 Ultrasound 191 220 398 412 PCS 84 81 193 146 PDx 152 115 307 253 Other (a) 6 (3) 8 (5) 711 719 1,375 1,318 Restructuring costs (19) (10) (31) (22) Acquisition and disposition-related benefits (charges) 2 (14) 1 (29) Gain/(loss) of business and asset dispositions — — — 3 Spin-Off and separation costs (72) — (130) — Amortization of acquisition-related intangible assets (32) (30) (63) (63) Investment revaluation gain (loss) (6) (14) (1) (22) Interest and other financial charges – net (137) (12) (273) (16) Non-operating benefit income (costs) 123 1 238 3 Income from continuing operations before income taxes $ 570 $ 639 $ 1,116 $ 1,172 (a) Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other business activities which do not meet the definition of an operating segment.

RECEIVABLES

RECEIVABLES	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
RECEIVABLES	RECEIVABLES Current Receivables As of June 30, 2023 December 31, 2022 Current customer receivables (a) $ 3,154 $ 3,112 Non-income based tax receivables 196 174 Other sundry receivables 112 100 Sundry receivables 308 274 Allowance for credit losses (92) (91) Total current receivables – net $ 3,370 $ 3,295 (a) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $140 million and $157 million as of June 30, 2023 and December 31, 2022, respectively. The decrease in chargebacks is primarily due to lower wholesaler product levels. Long-Term Receivables As of June 30, 2023 December 31, 2022 Long-term customer receivables $ 67 $ 80 Sundry receivables 76 57 Non-income based tax receivables 28 28 Supplier advances 11 11 Allowance for credit losses (30) (31) Total long-term receivables – net (a) $ 152 $ 145 (a) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

FINANCING RECEIVABLES

FINANCING RECEIVABLES	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
FINANCING RECEIVABLES	FINANCING RECEIVABLES Financing Receivables As of June 30, 2023 December 31, 2022 Loans, net of deferred income $ 32 $ 29 Investment in financing leases, net of deferred income 73 72 Allowance for credit losses (4) (4) Current financing receivables – net (a) 101 97 Loans, net of deferred income 43 44 Investment in financing leases, net of deferred income 157 158 Allowance for credit losses (5) (6) Non-current financing receivables – net (a) $ 195 $ 196 (a) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Condensed Consolidated and Combined Statements of Financial Position. As of June 30, 2023 , 5%, 4%, and 5% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2022 , 7%, 6%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
LEASES	LEASES OPERATING LEASE LIABILITIES. Operating lease liabilities recognized within All other current liabilities or All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position were $370 million and $347 million as of June 30, 2023 and December 31, 2022, respectively. Expense related to our operating lease portfolio was $57 million and $40 million for the three months ended June 30, 2023 and 2022, respectively, and $113 million and $96 million for the six months ended June 30, 2023 and 2022, respectively.

ACQUISITIONS, GOODWILL, AND OTH

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS ACQUISITIONS. On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million future holdback payment and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to AI-guided ultrasound screening for novice users. See Note 12, “Financial Instruments and Fair Value Measurements ” for further information about the fair value measurement of contingent consideration. Goodwill Balance as of December 31, 2022 Acquisitions Foreign exchange and other Balance as of June 30, 2023 Imaging (a) $ 4,409 $ 16 $ 2 $ 4,427 Ultrasound 3,835 94 1 3,930 PCS 2,036 — 2 2,038 PDx 2,533 — 1 2,534 Total Goodwill $ 12,813 $ 110 $ 6 $ 12,929 (a) Includes the acquisition of IMACTIS SAS (“Imactis”) in the second quarter of 2023. Imactis is a French company that provides electromagnetic navigation solutions for image-guided procedures in computed tomography. We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date. Substantially all other intangible assets are subject to amortization. Intangible assets decreased during the six months ended June 30, 2023, primarily as a result of amortization, partially offset by acquisitions in our Imaging and Ultrasound segments. Amortization expense was $93 million and $101 million for the three months ended June 30, 2023 and 2022, respectively, and $189 million and $204 million for the six months ended June 30, 2023 and 2022, respectively.
ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS	ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS ACQUISITIONS. On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million future holdback payment and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to AI-guided ultrasound screening for novice users. See Note 12, “Financial Instruments and Fair Value Measurements ” for further information about the fair value measurement of contingent consideration. Goodwill Balance as of December 31, 2022 Acquisitions Foreign exchange and other Balance as of June 30, 2023 Imaging (a) $ 4,409 $ 16 $ 2 $ 4,427 Ultrasound 3,835 94 1 3,930 PCS 2,036 — 2 2,038 PDx 2,533 — 1 2,534 Total Goodwill $ 12,813 $ 110 $ 6 $ 12,929 (a) Includes the acquisition of IMACTIS SAS (“Imactis”) in the second quarter of 2023. Imactis is a French company that provides electromagnetic navigation solutions for image-guided procedures in computed tomography. We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date. Substantially all other intangible assets are subject to amortization. Intangible assets decreased during the six months ended June 30, 2023, primarily as a result of amortization, partially offset by acquisitions in our Imaging and Ultrasound segments. Amortization expense was $93 million and $101 million for the three months ended June 30, 2023 and 2022, respectively, and $189 million and $204 million for the six months ended June 30, 2023 and 2022, respectively.

BORROWINGS

BORROWINGS	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
BORROWINGS	BORROWINGS The Company’s borrowings include the following senior unsecured notes and credit agreements: Senior Unsecured Notes The Company’s long-term borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”). Refer to the table below for further information about the Notes. Credit Facilities The Company has credit agreements providing for: • a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million; • a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million; and • a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”). There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility as of June 30, 2023 or December 31, 2022. On January 3, 2023, the Company completed a $2,000 million drawdown of the floating rate Term Loan Facility in connection with the Spin-Off from GE. The weighted average interest rate for the Notes and our Credit Facilities for the six months ended June 30, 2023 was 5.98%. We had no principal debt repayments on the Notes or the Term Loan Facility for the six months ended June 30, 2023. Long-Term Borrowings Composition As of June 30, 2023 December 31, 2022 5.550% senior notes due November 15, 2024 $ 1,000 $ 1,000 5.600% senior notes due November 15, 2025 1,500 1,500 5.650% senior notes due November 15, 2027 1,750 1,750 5.857% senior notes due March 15, 2030 1,250 1,250 5.905% senior notes due November 22, 2032 1,750 1,750 6.377% senior notes due November 22, 2052 1,000 1,000 Floating rate Term Loan Facility 2,000 — Other 32 38 Total principal debt issued 10,282 8,288 Less: Unamortized debt issuance costs and discounts 44 47 Less: Current portion of long-term borrowings 5 7 Long-term borrowings, net of current portion $ 10,233 $ 8,234 See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated cross-currency interest rate swaps. LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

POSTRETIREMENT BENEFIT PLANS

POSTRETIREMENT BENEFIT PLANS	6 Months Ended
	Jun. 30, 2023
Retirement Benefits [Abstract]
POSTRETIREMENT BENEFIT PLANS	POSTRETIREMENT BENEFIT PLANS PENSION BENEFITS AND RETIREE HEALTH AND LIFE BENEFITS SPONSORED BY GE, TRANSFERRED TO GE HEALTHCARE IN CONNECTION WIT H THE SPIN-OFF. C ertain GE HealthCare employees were covered under various pension and retiree health and life plans sponsored by GE prior to the Spin-Off, including principal pension plans, other pension plans, and principal retiree benefit plans. A subset of these pension plans have been closed to new participants. For the three and six months ended June 30, 2022, relevant participation costs for these plans were allocated to the Company and recognized within the Condensed Combined Statement of Income. These included service costs for active employees in the U.S. GE Pension Plan, certain international pension plans, the U.S. GE Supplementary Pension Plan, and the U.S. retiree benefit plan. We did not record any liabilities associated with our participation in these plans in our Condensed Combined Statement of Financial Position as of December 31, 2022. Expenses associated with our employees’ participation in the U.S. GE principal pension and principal retiree benefit plans, which represent the majority of related expense, were $25 million and $49 million for the three and six months ended June 30, 2022. Expenses associated with our employees’ participation in GE’s non-U.S. based pension plans were $12 million and $16 million for the three and six months ended June 30, 2022. In connection with the Spin-Off, on January 1, 2023, these plans were separated and GE transferred certain liabilities and assets of these plans to GE HealthCare based upon measurements as of December 31, 2022. The amounts assumed by GE HealthCare on January 1, 2023, are shown in the tables below. Accumulated Benefit Obligations and Unrecognized Gain As of January 1, 2023 Defined benefit plans Other postretirement plans Total Accumulated benefit obligations $ 21,696 $ 1,210 $ 22,906 Unrecognized gain to be recorded in AOCI 1,258 1,223 2,481 Net Benefit Liability As of January 1, 2023 Defined benefit plans Other postretirement plans Total Projected benefit obligations $ 21,743 $ 1,210 $ 22,953 Fair value of assets 18,908 — 18,908 Net liability $ 2,835 $ 1,210 $ 4,045 PENSION PLANS SPONSORED BY GE HEALTHCARE, INCLUDING THOSE TRANSFERRED BY GE. As the pension plans were transferred by GE on January 1, 2023, there are no amounts included for these plans in the periods ended June 30, 2022. Pension plans with pension assets or obligations less than $50 million and $20 million as of June 30, 2023 and 2022, respectively, are not included in the results below. Components of Expense (Income) For the three months ended June 30 Defined benefit plans Other postretirement plans 2023 2022 2023 2022 Service cost – Operating $ 15 $ 5 $ 2 $ — Interest cost 290 5 15 — Expected return on plan assets (357) (7) — — Amortization of net loss (gain) (32) 1 (16) — Amortization of prior service cost (credit) (1) (1) (22) — Non-operating $ (100) $ (2) $ (23) $ — Net periodic expense (income) $ (85) $ 3 $ (21) $ — For the six months ended June 30 Defined benefit plans Other postretirement plans 2023 2022 2023 2022 Service cost – Operating $ 29 $ 10 $ 4 $ — Interest cost 582 9 30 — Expected return on plan assets (713) (14) — — Amortization of net loss (gain) (61) 3 (32) — Amortization of prior service cost (credit) (2) (2) (44) — Non-operating $ (194) $ (4) $ (46) $ — Net periodic expense (income) $ (165) $ 6 $ (42) $ — For the six months ended June 30, 2023, the Company made contributions for benefit payments totaling $107 million to the pension plans and $73 million to its postretirement plans. During 2023, the Company expects to make total benefit payments of approximately $353 million to our defined benefit pension and postretirement plans for benefit payments. The Company does not have a required minimum cash pension contribution obligation for its U.S. plans in 2023. Future contributions will depend on market conditions, interest rates, and other factors. Prior to the Spin-Off, we disclosed postretirement plans with assets or obligations that exceeded $20 million. As a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023, we now present postretirement plans with assets or obligations that exceed $50 million. For the year, the Company expects to contribute approximately $11 million to postretirement plans that are no longer disclosed. Defined Contribution Plan As a result of the Spin-Off, GE HealthCare established a defined contribution plan for its eligible U.S. employees that was largely consistent with the plan th ey participated in while GE HealthCare operated as a business of GE. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan in 2023 and GE’s defined contribution plan in 2022 represent the employer matching contributions for GE HealthCare employees and we

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Our income tax rate was 24.0% and 23.9% for the three months ended June 30, 2023 and 2022, respectively, and 26.9% and 24.2% for the six months ended June 30, 2023 and 2022, respectively. The tax rate for 2023 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations, withholding taxes, and state taxes. The tax rate for 2022 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations and state taxes. The Company is currently being audited in a number of jurisdictions for tax years 2004-2021, including China, Egypt, France, Germany, Norway, the United Kingdom, and the U.S. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions from within “Interest and other financial charges – net” to within “Benefit (provision) for income taxes.” See Note 1, “Organization and Basis of Presentation” for further information. Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in the first quarter of 2023, an incremental deferred tax liability of $30 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. Also, in connection with the Spin-Off, our net deferred income tax assets inc reased by $3,099 million primarily due to transfers from GE, including $964 million related to pension and postretirement benefits, with the remainder primarily attributable to tax attributes that were not part of the Company’s stand-alone operations and changes to valuation on a GE HealthCare basis.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET Changes in Accumulated other comprehensive income (loss) ( “ AOCI ” ) by component, net of income taxes, were as follows: For the three months ended June 30, 2023 Currency translation adjustments (a) Benefit plans Cash flow hedges Total AOCI March 31, 2023 $ (1,760) $ 1,865 $ (30) $ 75 Other comprehensive income (loss) before reclasses – net of taxes of $28, $(11), and $(2) 3 36 5 44 Reclasses from AOCI – net of taxes of $0, $17, and $(1) (c) — (54) 5 (49) June 30, 2023 $ (1,757) $ 1,847 $ (20) $ 70 For the three months ended June 30, 2022 Currency translation adjustments Benefit plans Cash flow hedges Total AOCI March 31, 2022 $ (1,122) $ (105) $ 56 $ (1,171) Other comprehensive income (loss) before reclasses – net of taxes of $(12), $(1), and $4 (472) 3 (3) (472) Reclasses from AOCI – net of taxes of $0, $0, and $0 (c) — — (6) (6) June 30, 2022 $ (1,594) $ (102) $ 47 $ (1,649) For the six months ended June 30, 2023 Currency translation adjustments (a)(d) Benefit plans Cash flow hedges Total AOCI December 31, 2022 $ (1,845) $ (42) $ 9 $ (1,878) Other comprehensive income (loss) before reclasses – net of taxes of $17, $(9), and $2 88 23 (8) 103 Unrecognized gain transferred from GE pension – net of taxes of $0, $(509), and $0 (b) — 1,972 — 1,972 Reclasses from AOCI – net of taxes of $0, $33, and $6 (c) — (106) (21) (127) June 30, 2023 $ (1,757) $ 1,847 $ (20) $ 70 For the six months ended June 30, 2022 Currency translation adjustments Benefit plans Cash flow hedges Total AOCI December 31, 2021 $ (969) $ (100) $ 32 $ (1,037) Other comprehensive income (loss) before reclasses – net of taxes of $(14), $(10), and $(2) (625) (2) 32 (595) Reclasses from AOCI – net of taxes of $0, $0, and $0 (c) — — (17) (17) June 30, 2022 $ (1,594) $ (102) $ 47 $ (1,649) (a) The amount of foreign currency translation recognized in Other comprehensive income (loss) during the six months ended June 30, 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “ Financial Instruments and Fair Value Measurements. ” (b) Refer to Note 9, “ Postretirement Benefit Plans ” for further information on the unrecognized gain transferred from the GE pension and other postretirement plans in connection with the Spin-Off. (c) Reclassifications from AOCI into earnings for Benefit plans are recognized within Non-operating benefit (income) loss, while Cash flow hedges are recognized within Cost of products or Cost of services in our Condensed Consolidated and Combined Statements of Income. (d) Other comprehensive income (loss) before reclassification for Currency translation adjustments includes $28 million associated with Spin-Off related adjustments.

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS DERIVATIVES AND HEDGING. Our primary objective in executing and holding derivatives is to reduce the earnings and cash flow volatility associated with fluctuations in foreign currency exchange rates and commodity prices and hedge the volatility associated with the translation of the assets and liabilities of subsidiaries with a different functional currency than the USD. These hedge contracts reduce, but do not entirely eliminate, the impact of foreign currency rate and commodity price movements. The Company does not enter into or hold derivative instruments for speculative trading purposes. Cash Flow Hedges The total amount in AOCI related to cash flow hedges of foreign currency-denominated forecasted transactions was a net $20 million loss as of June 30, 2023. We expect to reclassify $14 million of pre-tax net deferred losses associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the earnings effects of the related forecasted transactions. Pre-tax gains (losses) reclassified from AOCI into earnings were $(6) million and $6 million, for the three months ended June 30, 2023 and 2022, respectively and $27 million and $17 million for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, the maximum length of time over which we are hedging our forecasted transactions was approximately two years. Net Investment Hedges The Company uses derivative instruments to hedge the currency risk associated with its net investment in foreign operations. The derivative instruments include cross-currency swaps and foreign currency forward contracts in combination with foreign currency options contracts. As of June 30, 2023 and December 31, 2022, the Company had $2,296 million and $2,132 million notional, respectively, of derivatives consisting mainly of receive-fixed USD, pay-fixed Euro ( “ EUR ” ) cross-currency swaps, each designated as the hedging instruments in net investment hedging relationships in order to mitigate the foreign currency risk attributable to the translation of its net investment in certain EUR-functional subsidiaries. The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated: Fair Value of Derivatives June 30, 2023 December 31, 2022 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency exchange contracts $ 1,206 $ 34 $ 56 $ 1,240 $ 32 $ 53 Derivatives accounted for as cash flow hedges 1,206 34 56 1,240 32 53 Cross-currency swaps 2,197 29 211 2,132 — 111 Foreign currency exchange contracts and options 99 3 2 — — — Derivatives accounted for as net investment hedges 2,296 32 213 2,132 — 111 Foreign currency exchange contracts 5,269 34 24 4,456 9 20 Embedded derivatives 683 20 13 604 24 18 Equity contracts 198 31 3 8 — 6 Commodity derivatives 77 1 3 48 1 1 Derivatives not designated as hedges 6,227 86 43 5,116 34 45 Total derivatives $ 9,729 $ 152 $ 312 $ 8,488 $ 66 $ 209 Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis on our Condensed Consolidated and Combined Statements of Financial Position and in the table above. The fair value of the derivatives contracts is recognized within All other current assets, All other assets, All other current liabilities, and All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position based upon the contractual timing of settlements for these contracts. As of June 30, 2023, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $64 million. The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges: Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Cash flow hedges $ 7 $ (7) $ (10) $ 34 Net investment hedges (36) — (71) — The tables below present the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income: Derivative Financial Instruments For the three months ended June 30, 2023 For the three months ended June 30, 2022 Cost of products Cost of services Selling, general and administrative Other (a) Cost of products Cost of services Selling, general and administrative Other (a) Foreign currency exchange contracts $ (5) $ (1) $ — $ — $ 5 $ 1 $ — $ — Effects of cash flow hedges (5) (1) — — 5 1 — — Foreign currency exchange contracts 3 1 — 4 (60) (11) — 7 Embedded derivatives — — — 2 — — — 5 Equity contracts — — 18 — — — — (1) Commodity derivatives — — — (2) — — — 5 Effects of derivatives not designated as hedges $ 3 $ 1 $ 18 $ 4 $ (60) $ (11) $ — $ 16 Derivative Financial Instruments For the six months ended June 30, 2023 For the six months ended June 30, 2022 Cost of products Cost of services Selling, general and administrative Other (a) Cost of products Cost of services Selling, general and administrative Other (a) Foreign currency exchange contracts $ 22 $ 5 $ — $ — $ 14 $ 3 $ — $ — Effects of cash flow hedges 22 5 — — 14 3 — — Foreign currency exchange contracts 10 3 — 5 (61) (11) — 7 Embedded derivatives — — — 1 — — — 8 Equity contracts — — 33 3 — — — (1) Commodity derivatives — — — (4) — — — 15 Effects of derivatives not designated as hedges $ 10 $ 3 $ 33 $ 5 $ (61) $ (11) $ — $ 29 (a) Amounts inclusive of Other income (expense) – net on the Condensed Consolidated and Combined Statements of Income. FAIR VALUE MEASUREMENTS. The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis: Fair Value of Financial Assets and Liabilities As of June 30, 2023 As of December 31, 2022 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Investment securities $ 30 $ — $ — $ 30 $ 21 $ — $ — $ 21 Derivatives — 152 — 152 — 66 — 66 Liabilities: Deferred compensation (a) 243 3 — 246 62 2 — 64 Derivatives — 309 3 312 — 203 6 209 Contingent consideration — — 65 65 — — 42 42 (a) Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off. Contingent Consideration The contingent consideration liabilities as of June 30, 2023 and December 31, 2022 were recorded in connection with business acquisitions. Changes in the Level 3 fair value measurement of contingent consideration were not material during the six months ended June 30, 2023. Fair Value of Other Financial Instruments The estimated fair value of long-term debt (including the current portion) as of June 30, 2023 and December 31, 2022 , was $10,630 million and $8,512 million compared to a carrying value (which includes a reduction for amortized debt issuance costs and discounts) of $10,238 million and $8,241 million, respectively. The fair value of our borrowings is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” for further information. Non-recurring Fair Value Measurements Equity investments without readily determinable fair value as of June 30, 2023 and December 31, 2022

COMMITMENTS, GUARANTEES, PRODUC

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES	COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES GUARANTEES. The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings" for further information. In addition, GE has provided parent company guarantees in certain jurisdictions where we lack the legal structure to issue the requisite guarantees required on certain projects. Following the Spin-Off, which was completed pursuant to a Separation and Distribution Agreement (the "Separation and Distribution Agreement"), the Company has remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE is obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could be obligated to make payments under the applicable instruments for which GE is obligated to reimburse and indemnify the Company. As of June 30, 2023 the Company’s maximum aggregate exposure, subject to GE reimbursement, is approximately $114 million. PRODUCT WARRANTIES. We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows. Product Warranties For the six months ended June 30 2023 2022 Balance at beginning of period $ 193 $ 161 Current-year provisions 102 131 Expenditures (105) (104) Other changes — (5) Balance at end of period $ 190 $ 183 Product warranties are recognized within All other current liabilities in the Condensed Consolidated and Combined Statements of Financial Position. In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matter described below that could have a material impact on our results of operations. In many proceedings, including the specific matter described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated. Contracts with Iraqi Ministry of Health In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (“the D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. Also in February 2023, defendants filed a motion for a temporary, partial stay of further district court proceedings until the Supreme Court issues its decision in a separate case, Twitter, Inc. v. Taamneh, which also involves the U.S. Anti-Terrorism Act. In March 2023, the District Court granted the motion for a temporary, partial stay. In May 2023, the Supreme Court issued its opinion in Twitter, Inc. v. Taamneh, and the partial stay was extended by the District Court pending further submissions by the parties. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision.

RESTRUCTURING AND OTHER ACTIVIT

RESTRUCTURING AND OTHER ACTIVITIES - NET	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND OTHER ACTIVITIES - NET	RESTRUCTURING AND OTHER ACTIVITIES – NET Restructuring activities are essential to optimize the business operating model for GE HealthCare as a stand-alone company and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring and other charges (gains) primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring and other activities are not allocated. As a result of committed restructuring initiatives, we recorded net expenses of $19 million and $10 million for the three months ended June 30, 2023 and 2022 and $31 million and $22 million for the six months ended June 30, 2023 and 2022. These restructuring initiatives are expected to result in additional expenses of approximately $35 million, to be incurred primarily in 2023, substantially related to employee-related termination benefits and facility exit costs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or Selling, general, and administrative ("SG&A"), as appropriate, in the Condensed Consolidated and Combined Statements of Income. Restructuring and Other Activities For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Employee termination costs $ 15 $ 9 $ 25 $ 18 Facility and other exit costs — 1 1 4 Asset write-downs 4 — 5 — Total restructuring and other activities – net $ 19 $ 10 $ 31 $ 22

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION Stock options provide employees the opportunity to purchase GE HealthCare shares in the future at the market price of our stock on the date the award is granted (the strike price). The options become exercisable over the vesting period, typically becoming fully vested in three The following tables provide the weighted average fair value of options, RSUs, and PSUs granted to employees during the six months ended June 30, 2023 and the related stock option valuation assumptions used in the Black-Scholes model: Weighted Average Grant Date Fair Value (In dollars) June 30, 2023 Stock options $ 25 RSUs 73 PSUs 84 Key Assumptions in the Black-Scholes Valuation for Stock Options June 30, 2023 Risk free rate 3.6 % Dividend yield 0.01 % Expected volatility 26.2 % Expected term (in years) 6.2 Strike price (in dollars) $ 72 Share-Based Compensation Activity Stock options RSUs Shares (in thousands) Weighted average exercise price (in dollars) Weighted average contractual term (in years) Intrinsic value (in millions) Shares (in thousands) Weighted average grant date fair value (in dollars) Weighted average contractual term (in years) Intrinsic value (in millions) Outstanding as of January 4, 2023 (a) 3,738 $ 90 3,551 $ 58 Granted 2,143 72 1,788 73 Exercised/Vested (448) 60 (672) 70 Forfeited (31) 69 (158) 62 Expired (30) 131 — — Outstanding as of June 30, 2023 5,372 $ 85 6.4 $ 53 4,509 $ 63 1.8 $ 368 Exercisable as of June 30, 2023 3,044 $ 95 4.0 $ 31 N/A N/A N/A N/A Expected to vest 1,780 $ 72 9.5 $ 17 3,851 $ 55 1.8 $ 313 (a) Our common stock began “regular way” trading on The Nasdaq Global Market on January 4, 2023. The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off. Total outstanding PSUs as of June 30, 2023 were 1,293 thousand shares with a weighted average fair value of $85 dollars. The intrinsic value and weighted average contractual term of PSUs outstanding were $105 million and 1.8 years, respectively. Share-based compensation expense is recognized within Cost of products, Cost of services, SG&A or Research and development (“R&D”), as appropriate, in the Condensed Consolidated Statement of Income. Share-based Compensation Expense For the three months ended For the six months ended June 30, 2023 June 30, 2023 Share-based compensation expense (pre-tax) $ 28 $ 52 Income tax benefits (3) (11) Share-based compensation expense (after-tax) $ 25 $ 41 Other Share-based Compensation Data Unrecognized compensation expense as of June 30, 2023 (a) $ 202 Cash received from stock options exercised for the six months ended June 30, 2023 27 Intrinsic value of stock options exercised and RSU/PSUs vested in the six months ended June 30, 2023 57 (a) Amortized over a weighted average period of 2.2 years.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for all periods through December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date and is net of Net (income) loss attributable to noncontrolling interest which is fully associated with continuing operations. Earnings Per Share For the three months ended June 30 For the six months ended June 30 (In millions, except per share amounts) 2023 2022 2023 2022 Numerator: Net income from continuing operations $ 433 $ 486 $ 816 $ 888 Net (income) attributable to noncontrolling interests (15) (13) (26) (26) Net income from continuing operations attributable to GE HealthCare 418 473 790 862 Deemed preferred stock dividend of redeemable noncontrolling interest — — (183) — Net income from continuing operations attributable to GE HealthCare common shareholders 418 473 607 862 Income from discontinued operations, net of taxes — 12 — 12 Net income attributable to GE HealthCare common stockholders $ 418 $ 485 $ 607 $ 874 Denominator: Basic weighted-average shares outstanding 455 454 455 454 Dilutive effect of common stock equivalents 3 — 3 — Diluted weighted-average shares outstanding 458 454 458 454 Basic Earnings Per Share: Continuing operations $ 0.92 $ 1.04 $ 1.34 $ 1.90 Discontinued operations — 0.03 — 0.03 Attributable to GE HealthCare common stockholders 0.92 1.07 1.34 1.93 Diluted Earnings Per Share: Continuing operations $ 0.91 $ 1.04 $ 1.33 $ 1.90 Discontinued operations — 0.03 — 0.03 Attributable to GE HealthCare common stockholders 0.91 1.07 1.33 1.93 Antidilutive securities (a) 4 — 4 — (a) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL INFORMATION	SUPPLEMENTAL FINANCIAL INFORMATION Cash, Cash Equivalents and Restricted Cash As of June 30, 2023 December 31, 2022 Cash and cash equivalents $ 1,936 $ 1,440 Short-term restricted cash 3 5 Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position 1,939 1,445 Long-term restricted cash (a) 6 6 Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows $ 1,945 $ 1,451 (a) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position. Inventories As of June 30, 2023 December 31, 2022 Raw materials $ 1,103 $ 1,053 Work in process 106 91 Finished goods 1,055 1,011 Inventories (a) $ 2,264 $ 2,155 (a) Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position. Property, Plant, and Equipment - Net As of June 30, 2023 December 31, 2022 Original cost $ 5,075 $ 4,989 Less accumulated depreciation and amortization (3,057) (2,988) Right-of-use operating lease assets 339 313 Property, plant, and equipment - net $ 2,357 $ 2,314 ALL OTHER CURRENT AND NON-CURRENT ASSETS. All other current assets primarily include prepaid expenses and deferred costs, derivative instruments, and financing receivables. All other non-current assets primarily include pension assets, equity method and other investments, long-term financing receivables, long-term customer and sundry receivables, long-term contract and other deferred assets, and long-term inventories. All other current and non-current assets increased in the six months ended June 30, 2023, primarily due to assets transferred from GE as a result of the Spin-Off. Refer to Note 1, “Organization and Basis of Presentation” for further information. ALL OTHER CURRENT AND NON-CURRENT LIABILITIES. All other current liabilities primarily include employee compensation and benefits liabilities, sales allowances, equipment projects and other commercial liabilities, product warranties, uncertain and other income tax payable, accrued freight and utilities, operating lease liabilities, and derivative instruments. All other non-current liabilities primarily include long-term contract liabilities, long-term operating lease liabilities, long-term environmental, health and safety obligations, long-term derivative instruments and long-term uncertain and other income tax payable. All other current and non-current liabilities increased in the six months ended June 30, 2023, primarily due to liabilities transferred from GE as a result of the Spin-Off. Refer to Note 1, “Organization and Basis of Presentation” for further information. SUPPLY CHAIN FINANCE PROGRAMS. The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance program, payment terms normally range from 30 to 150 days, not exceeding 180 days, depending on the underlying supplier agreements. Included in Accounts payable as of June 30, 2023 and December 31, 2022 were $422 million and $392 million, respectively, of confirmed supplier invoices that are outstanding and subject to the third-party programs. REDEEMABLE NONCONTROLLING INTERESTS . The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events, such as a change of control of the Company. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated and Combined Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable or probable of becoming redeemable are subsequently adjusted to the greater of current redemption value or initial carrying value. A change of control is generally not considered probable until it occurs. The activity attributable to redeemable noncontrolling interests for the six months ended June 30, 2023 and 2022 is presented below. Redeemable Noncontrolling Interests For the six months ended June 30 2023 2022 Balance at beginning of period $ 230 $ 220 Net income attributable to redeemable noncontrolling interests 21 19 Redemption value adjustments (a) 183 — Distributions to and exercise of redeemable noncontrolling interests (b) (225) (19) Balance at end of period $ 209 $ 220 (a) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. These redeemable noncontrolling interests were remeasured to their current redemption value resulting in a redemption value adjustment of $183 million. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to retained earnings. (b) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023. Other Income (Expense) – Net For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Net interest and investment income (expense) $ — $ (10) $ 13 $ (12) Equity method investment income 5 6 9 9 Change in fair value of assumed obligation (6) — (19) — Other items, net (a) 15 23 19 48 Total other income (expense) – net $ 14 $ 19 $ 22 $ 45 (a) Other items, net primarily consists of lease income, licensing and royalty income, and gains and losses related to derivatives for the three and six months ended June 30, 2023, and licensing and royalty income, and gains and losses related to derivatives for the three and six months ended June 30, 2022.

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES PRIOR TO SPIN-OFF. Prior to the Spin-Off, GE provided the Company with significant corporate infrastructure and shared services. Some of these services continue to be provided by GE to the Company on a temporary basis under the Transition Services Agreement, as discussed below. The following disclosures summarize related party activity between GE HealthCare and GE. This activity, which occurred prior to the Spin-Off, is included in the condensed combined financial statements. Pensions, Benefit, and Contribution Plans As discussed in Note 9, “Postretirement Benefit Plans,” employees of the Company participated in pensions, benefit, and contribution plans that were sponsored by GE. The Company was charged $64 million and $123 million for the three and six months ended June 30, 2022 related to employee participation in these plans. In connection with the Spin-Off, a portion of these plans were transferred to the Company. Share-based Compensation GE granted various employee benefits to its group employees, including those of the Company, under the GE Long-Term Incentive Plan. These benefits primarily included stock options and restricted stock units. Compensation expense allocated to the Company was $20 million and $39 million for the three and six months ended June 30, 2022, respectively, and is recognized within SG&A in the Condensed Combined Statement of Income. Corporate Overhead and Other Allocations from GE GE provided certain services described below that were charged to the Company based on employee headcount, revenue, or other allocation methodologies. Corporate Allocations from GE For the three months ended For the six months ended June 30, 2022 June 30, 2022 Costs for centralized services (a) $ 13 $ 26 Costs associated with employee medical insurance (b) 30 60 Costs for corporate and shared services (c) 104 220 (a) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Condensed Combined Statement of Income. (b) Costs associated with employee medical insurance were recognized within Cost of products, Cost of services, SG&A, and R&D in the Condensed Combined Statement of Income based on the employee population. (c) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Condensed Combined Statement of Income. Management believes that the expense and cost allocations have been determined on a basis that is a reasonable reflection of the utilization of services provided or the benefit received by the Company during the three and six months ended June 30, 2022. The amounts that would have been, or will be incurred, on a stand-alone basis could materially differ from the amounts allocated due to economies of scale, difference in management judgment, a requirement for more or fewer employees, or other factors. AFTER SPIN-OFF. In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including, but not limited to the following which had activity during the first six months of 2023: • Separation and Distribution Agreement – sets forth the principal actions to be taken in connection with the Spin-Off, including the transfer of assets and assumption of liabilities, and establishes certain rights and obligations between the Company and GE following the Distribution, including procedures with respect to claims subject to indemnification and related matters. • Transition Services Agreement – governs all matters relating to the provision of services between the Company and GE on a transitional basis. The services the Company receives include support for digital technology, human resources, supply chain, finance, and real estate services, among others. The services generally commenced on the date of the Spin-Off and will terminate up to 36 months following the Distribution Date depending upon the related transitional service. For the three and six months ended June 30, 2023, we incurred $84 million and $192 million, net, which represents fees charged from GE to the Company primarily for information technology, human resources, and R&D and is net of fees charged from the Company to GE for facilities and other shared services. • Tax Matters Agreement (“TMA”) – governs the respective rights, responsibilities, and obligations between the Company and GE with respect to all tax matters (excluding employee-related taxes covered under the Employee Matters Agreement), in addition to certain restrictions which generally prohibit us from taking or failing to take any action in the two-year period following the Distribution that would prevent the Distribution from qualifying as tax-free for U.S. federal income tax purposes, including limitations on our ability to pursue certain strategic transactions. The TMA specifies the portion of tax liability for which the Company will bear contractual responsibility, and the Company and GE will each agree to indemnify each other against any amounts for which such indemnified party is not responsible. Current amounts due from and to GE under the various agreements described above are recognized within Due from related parties or Due to related parties, as applicable, in the Condensed Consolidated and Combined Statements of Financial Position. Non-current amounts due from GE were $88 million and due to GE were $132 million, and were recognized within All other assets or All other liabilities, as applicable, in the Condensed Consolidated Statements of Financial Position as of June 30, 2023. These amounts primarily relate to tax and other indemnities. GE HealthCare sells products and services in the ordinary course of business to certain entities associated with two members of our Board of Directors. During the three and six months ended June 30, 2023, we recognized revenue of $23 million and $47 million, respectively, from these entities in connection with providing products and services. Current amounts due from these entities as of June 30, 2023 were not significant.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net income attributable to GE HealthCare	$ 418	$ 485	$ 790	$ 874

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION. The condensed consolidated and combined financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations and comprehensive income for the three and six months ended June 30, 2023 and 2022, cash flows for the six months ended June 30, 2023 and 2022, and the financial position as of June 30, 2023 and December 31, 2022. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S dollars (“USD”) unless otherwise stated. Prior to the Spin-Off, the condensed combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The condensed combined financial statements do not purport to reflect what the results of operations, comprehensive income, financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity during the periods presented. The condensed consolidated and combined financial statements should be read in conjunction with the Company’s audited combined financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022.
CONSOLIDATION	All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated and combined financial statements.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.
ACCOUNTING CHANGES	ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes , provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the condensed consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest wa s previously presented within “Interest and other financial charges – net” and has changed to being presented within “Benefit (provision) for income taxes.” The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements reflected in the Condensed Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50) . The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 17, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Summary of Contract and Other Deferred Assets	Contract and Other Deferred Assets As of June 30, 2023 December 31, 2022 Contract assets $ 642 $ 584 Other deferred assets 402 405 Contract and other deferred assets 1,044 989 Non-current contract assets (a) 54 37 Non-current other deferred assets (a) 84 82 Total contract and other deferred assets $ 1,182 $ 1,108 (a) Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Total Revenues by Segment For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Imaging: Radiology $ 2,227 $ 2,064 $ 4,315 $ 3,982 Interventional Guidance 393 385 801 778 Total Imaging 2,620 2,449 5,116 4,760 Total Ultrasound 839 828 1,698 1,643 PCS: Monitoring Solutions 563 512 1,115 1,033 Life Support Solutions 207 201 436 396 Total PCS 770 713 1,551 1,429 Total PDx 568 478 1,126 962 Other (a) 20 16 33 33 Total revenues $ 4,817 $ 4,484 $ 9,524 $ 8,827 (a) Financial information not presented within the reportable segments, shown within the Other category, represents the Hea lthCar e Financial Services (“HFS”) business which does not meet the definition of an operating segment. Segment EBIT For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Segment EBIT Imaging $ 278 $ 306 $ 469 $ 512 Ultrasound 191 220 398 412 PCS 84 81 193 146 PDx 152 115 307 253 Other (a) 6 (3) 8 (5) 711 719 1,375 1,318 Restructuring costs (19) (10) (31) (22) Acquisition and disposition-related benefits (charges) 2 (14) 1 (29) Gain/(loss) of business and asset dispositions — — — 3 Spin-Off and separation costs (72) — (130) — Amortization of acquisition-related intangible assets (32) (30) (63) (63) Investment revaluation gain (loss) (6) (14) (1) (22) Interest and other financial charges – net (137) (12) (273) (16) Non-operating benefit income (costs) 123 1 238 3 Income from continuing operations before income taxes $ 570 $ 639 $ 1,116 $ 1,172 (a) Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other business activities which do not meet the definition of an operating segment.

RECEIVABLES (Tables)

RECEIVABLES (Tables)	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Schedule of Receivables	Current Receivables As of June 30, 2023 December 31, 2022 Current customer receivables (a) $ 3,154 $ 3,112 Non-income based tax receivables 196 174 Other sundry receivables 112 100 Sundry receivables 308 274 Allowance for credit losses (92) (91) Total current receivables – net $ 3,370 $ 3,295 (a) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $140 million and $157 million as of June 30, 2023 and December 31, 2022, respectively. The decrease in chargebacks is primarily due to lower wholesaler product levels. Long-Term Receivables As of June 30, 2023 December 31, 2022 Long-term customer receivables $ 67 $ 80 Sundry receivables 76 57 Non-income based tax receivables 28 28 Supplier advances 11 11 Allowance for credit losses (30) (31) Total long-term receivables – net (a) $ 152 $ 145 (a) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position. Financing Receivables As of June 30, 2023 December 31, 2022 Loans, net of deferred income $ 32 $ 29 Investment in financing leases, net of deferred income 73 72 Allowance for credit losses (4) (4) Current financing receivables – net (a) 101 97 Loans, net of deferred income 43 44 Investment in financing leases, net of deferred income 157 158 Allowance for credit losses (5) (6) Non-current financing receivables – net (a) $ 195 $ 196 (a) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Condensed Consolidated and Combined Statements of Financial Position.

FINANCING RECEIVABLES (Tables)

FINANCING RECEIVABLES (Tables)	6 Months Ended
	Jun. 30, 2023
Receivables [Abstract]
Schedule of Receivables	Current Receivables As of June 30, 2023 December 31, 2022 Current customer receivables (a) $ 3,154 $ 3,112 Non-income based tax receivables 196 174 Other sundry receivables 112 100 Sundry receivables 308 274 Allowance for credit losses (92) (91) Total current receivables – net $ 3,370 $ 3,295 (a) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $140 million and $157 million as of June 30, 2023 and December 31, 2022, respectively. The decrease in chargebacks is primarily due to lower wholesaler product levels. Long-Term Receivables As of June 30, 2023 December 31, 2022 Long-term customer receivables $ 67 $ 80 Sundry receivables 76 57 Non-income based tax receivables 28 28 Supplier advances 11 11 Allowance for credit losses (30) (31) Total long-term receivables – net (a) $ 152 $ 145 (a) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position. Financing Receivables As of June 30, 2023 December 31, 2022 Loans, net of deferred income $ 32 $ 29 Investment in financing leases, net of deferred income 73 72 Allowance for credit losses (4) (4) Current financing receivables – net (a) 101 97 Loans, net of deferred income 43 44 Investment in financing leases, net of deferred income 157 158 Allowance for credit losses (5) (6) Non-current financing receivables – net (a) $ 195 $ 196 (a) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Condensed Consolidated and Combined Statements of Financial Position.

ACQUISITIONS, GOODWILL, AND O_2

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill Balance as of December 31, 2022 Acquisitions Foreign exchange and other Balance as of June 30, 2023 Imaging (a) $ 4,409 $ 16 $ 2 $ 4,427 Ultrasound 3,835 94 1 3,930 PCS 2,036 — 2 2,038 PDx 2,533 — 1 2,534 Total Goodwill $ 12,813 $ 110 $ 6 $ 12,929 (a) Includes the acquisition of IMACTIS SAS (“Imactis”) in the second quarter of 2023. Imactis is a French company that provides electromagnetic navigation solutions for image-guided procedures in computed tomography.

BORROWINGS (Tables)

BORROWINGS (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-Term Borrowings	Long-Term Borrowings Composition As of June 30, 2023 December 31, 2022 5.550% senior notes due November 15, 2024 $ 1,000 $ 1,000 5.600% senior notes due November 15, 2025 1,500 1,500 5.650% senior notes due November 15, 2027 1,750 1,750 5.857% senior notes due March 15, 2030 1,250 1,250 5.905% senior notes due November 22, 2032 1,750 1,750 6.377% senior notes due November 22, 2052 1,000 1,000 Floating rate Term Loan Facility 2,000 — Other 32 38 Total principal debt issued 10,282 8,288 Less: Unamortized debt issuance costs and discounts 44 47 Less: Current portion of long-term borrowings 5 7 Long-term borrowings, net of current portion $ 10,233 $ 8,234

POSTRETIREMENT BENEFIT PLANS (T

POSTRETIREMENT BENEFIT PLANS (Tables)	6 Months Ended
	Jun. 30, 2023
Retirement Benefits [Abstract]
Schedule of Defined Benefit Plans	The amounts assumed by GE HealthCare on January 1, 2023, are shown in the tables below. Accumulated Benefit Obligations and Unrecognized Gain As of January 1, 2023 Defined benefit plans Other postretirement plans Total Accumulated benefit obligations $ 21,696 $ 1,210 $ 22,906 Unrecognized gain to be recorded in AOCI 1,258 1,223 2,481 Net Benefit Liability As of January 1, 2023 Defined benefit plans Other postretirement plans Total Projected benefit obligations $ 21,743 $ 1,210 $ 22,953 Fair value of assets 18,908 — 18,908 Net liability $ 2,835 $ 1,210 $ 4,045
Components of Net Periodic Expense	Components of Expense (Income) For the three months ended June 30 Defined benefit plans Other postretirement plans 2023 2022 2023 2022 Service cost – Operating $ 15 $ 5 $ 2 $ — Interest cost 290 5 15 — Expected return on plan assets (357) (7) — — Amortization of net loss (gain) (32) 1 (16) — Amortization of prior service cost (credit) (1) (1) (22) — Non-operating $ (100) $ (2) $ (23) $ — Net periodic expense (income) $ (85) $ 3 $ (21) $ — For the six months ended June 30 Defined benefit plans Other postretirement plans 2023 2022 2023 2022 Service cost – Operating $ 29 $ 10 $ 4 $ — Interest cost 582 9 30 — Expected return on plan assets (713) (14) — — Amortization of net loss (gain) (61) 3 (32) — Amortization of prior service cost (credit) (2) (2) (44) — Non-operating $ (194) $ (4) $ (46) $ — Net periodic expense (income) $ (165) $ 6 $ (42) $ —

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in Accumulated other comprehensive income (loss) ( “ AOCI ” ) by component, net of income taxes, were as follows: For the three months ended June 30, 2023 Currency translation adjustments (a) Benefit plans Cash flow hedges Total AOCI March 31, 2023 $ (1,760) $ 1,865 $ (30) $ 75 Other comprehensive income (loss) before reclasses – net of taxes of $28, $(11), and $(2) 3 36 5 44 Reclasses from AOCI – net of taxes of $0, $17, and $(1) (c) — (54) 5 (49) June 30, 2023 $ (1,757) $ 1,847 $ (20) $ 70 For the three months ended June 30, 2022 Currency translation adjustments Benefit plans Cash flow hedges Total AOCI March 31, 2022 $ (1,122) $ (105) $ 56 $ (1,171) Other comprehensive income (loss) before reclasses – net of taxes of $(12), $(1), and $4 (472) 3 (3) (472) Reclasses from AOCI – net of taxes of $0, $0, and $0 (c) — — (6) (6) June 30, 2022 $ (1,594) $ (102) $ 47 $ (1,649) For the six months ended June 30, 2023 Currency translation adjustments (a)(d) Benefit plans Cash flow hedges Total AOCI December 31, 2022 $ (1,845) $ (42) $ 9 $ (1,878) Other comprehensive income (loss) before reclasses – net of taxes of $17, $(9), and $2 88 23 (8) 103 Unrecognized gain transferred from GE pension – net of taxes of $0, $(509), and $0 (b) — 1,972 — 1,972 Reclasses from AOCI – net of taxes of $0, $33, and $6 (c) — (106) (21) (127) June 30, 2023 $ (1,757) $ 1,847 $ (20) $ 70 For the six months ended June 30, 2022 Currency translation adjustments Benefit plans Cash flow hedges Total AOCI December 31, 2021 $ (969) $ (100) $ 32 $ (1,037) Other comprehensive income (loss) before reclasses – net of taxes of $(14), $(10), and $(2) (625) (2) 32 (595) Reclasses from AOCI – net of taxes of $0, $0, and $0 (c) — — (17) (17) June 30, 2022 $ (1,594) $ (102) $ 47 $ (1,649) (a) The amount of foreign currency translation recognized in Other comprehensive income (loss) during the six months ended June 30, 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “ Financial Instruments and Fair Value Measurements. ” (b) Refer to Note 9, “ Postretirement Benefit Plans ” for further information on the unrecognized gain transferred from the GE pension and other postretirement plans in connection with the Spin-Off. (c) Reclassifications from AOCI into earnings for Benefit plans are recognized within Non-operating benefit (income) loss, while Cash flow hedges are recognized within Cost of products or Cost of services in our Condensed Consolidated and Combined Statements of Income. (d) Other comprehensive income (loss) before reclassification for Currency translation adjustments includes $28 million associated with Spin-Off related adjustments.

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Derivative Assets at Fair Value	The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated: Fair Value of Derivatives June 30, 2023 December 31, 2022 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency exchange contracts $ 1,206 $ 34 $ 56 $ 1,240 $ 32 $ 53 Derivatives accounted for as cash flow hedges 1,206 34 56 1,240 32 53 Cross-currency swaps 2,197 29 211 2,132 — 111 Foreign currency exchange contracts and options 99 3 2 — — — Derivatives accounted for as net investment hedges 2,296 32 213 2,132 — 111 Foreign currency exchange contracts 5,269 34 24 4,456 9 20 Embedded derivatives 683 20 13 604 24 18 Equity contracts 198 31 3 8 — 6 Commodity derivatives 77 1 3 48 1 1 Derivatives not designated as hedges 6,227 86 43 5,116 34 45 Total derivatives $ 9,729 $ 152 $ 312 $ 8,488 $ 66 $ 209
Schedule of Derivative Liabilities at Fair Value	The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated: Fair Value of Derivatives June 30, 2023 December 31, 2022 Gross Notional Fair Value – Assets Fair Value – Liabilities Gross Notional Fair Value – Assets Fair Value – Liabilities Foreign currency exchange contracts $ 1,206 $ 34 $ 56 $ 1,240 $ 32 $ 53 Derivatives accounted for as cash flow hedges 1,206 34 56 1,240 32 53 Cross-currency swaps 2,197 29 211 2,132 — 111 Foreign currency exchange contracts and options 99 3 2 — — — Derivatives accounted for as net investment hedges 2,296 32 213 2,132 — 111 Foreign currency exchange contracts 5,269 34 24 4,456 9 20 Embedded derivatives 683 20 13 604 24 18 Equity contracts 198 31 3 8 — 6 Commodity derivatives 77 1 3 48 1 1 Derivatives not designated as hedges 6,227 86 43 5,116 34 45 Total derivatives $ 9,729 $ 152 $ 312 $ 8,488 $ 66 $ 209
Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI	The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges: Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Cash flow hedges $ 7 $ (7) $ (10) $ 34 Net investment hedges (36) — (71) —
Effect of Derivatives Instruments on Statements of Income	The tables below present the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income: Derivative Financial Instruments For the three months ended June 30, 2023 For the three months ended June 30, 2022 Cost of products Cost of services Selling, general and administrative Other (a) Cost of products Cost of services Selling, general and administrative Other (a) Foreign currency exchange contracts $ (5) $ (1) $ — $ — $ 5 $ 1 $ — $ — Effects of cash flow hedges (5) (1) — — 5 1 — — Foreign currency exchange contracts 3 1 — 4 (60) (11) — 7 Embedded derivatives — — — 2 — — — 5 Equity contracts — — 18 — — — — (1) Commodity derivatives — — — (2) — — — 5 Effects of derivatives not designated as hedges $ 3 $ 1 $ 18 $ 4 $ (60) $ (11) $ — $ 16 Derivative Financial Instruments For the six months ended June 30, 2023 For the six months ended June 30, 2022 Cost of products Cost of services Selling, general and administrative Other (a) Cost of products Cost of services Selling, general and administrative Other (a) Foreign currency exchange contracts $ 22 $ 5 $ — $ — $ 14 $ 3 $ — $ — Effects of cash flow hedges 22 5 — — 14 3 — — Foreign currency exchange contracts 10 3 — 5 (61) (11) — 7 Embedded derivatives — — — 1 — — — 8 Equity contracts — — 33 3 — — — (1) Commodity derivatives — — — (4) — — — 15 Effects of derivatives not designated as hedges $ 10 $ 3 $ 33 $ 5 $ (61) $ (11) $ — $ 29 (a) Amounts inclusive of Other income (expense) – net on the Condensed Consolidated and Combined Statements of Income.
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis: Fair Value of Financial Assets and Liabilities As of June 30, 2023 As of December 31, 2022 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Investment securities $ 30 $ — $ — $ 30 $ 21 $ — $ — $ 21 Derivatives — 152 — 152 — 66 — 66 Liabilities: Deferred compensation (a) 243 3 — 246 62 2 — 64 Derivatives — 309 3 312 — 203 6 209 Contingent consideration — — 65 65 — — 42 42 (a) Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off.

COMMITMENTS, GUARANTEES, PROD_2

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranties	An analysis of changes in the liability for product warranties follows. Product Warranties For the six months ended June 30 2023 2022 Balance at beginning of period $ 193 $ 161 Current-year provisions 102 131 Expenditures (105) (104) Other changes — (5) Balance at end of period $ 190 $ 183

RESTRUCTURING AND OTHER ACTIV_2

RESTRUCTURING AND OTHER ACTIVITIES - NET (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	Restructuring and Other Activities For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Employee termination costs $ 15 $ 9 $ 25 $ 18 Facility and other exit costs — 1 1 4 Asset write-downs 4 — 5 — Total restructuring and other activities – net $ 19 $ 10 $ 31 $ 22

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Weighted Average Grant Date Fair Value and Share-Based Compensation Activity	The following tables provide the weighted average fair value of options, RSUs, and PSUs granted to employees during the six months ended June 30, 2023 and the related stock option valuation assumptions used in the Black-Scholes model: Weighted Average Grant Date Fair Value (In dollars) June 30, 2023 Stock options $ 25 RSUs 73 PSUs 84 Share-Based Compensation Activity Stock options RSUs Shares (in thousands) Weighted average exercise price (in dollars) Weighted average contractual term (in years) Intrinsic value (in millions) Shares (in thousands) Weighted average grant date fair value (in dollars) Weighted average contractual term (in years) Intrinsic value (in millions) Outstanding as of January 4, 2023 (a) 3,738 $ 90 3,551 $ 58 Granted 2,143 72 1,788 73 Exercised/Vested (448) 60 (672) 70 Forfeited (31) 69 (158) 62 Expired (30) 131 — — Outstanding as of June 30, 2023 5,372 $ 85 6.4 $ 53 4,509 $ 63 1.8 $ 368 Exercisable as of June 30, 2023 3,044 $ 95 4.0 $ 31 N/A N/A N/A N/A Expected to vest 1,780 $ 72 9.5 $ 17 3,851 $ 55 1.8 $ 313 (a) Our common stock began “regular way” trading on The Nasdaq Global Market on January 4, 2023. The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off.
Schedule of Stock Options Valuation Assumptions	Key Assumptions in the Black-Scholes Valuation for Stock Options June 30, 2023 Risk free rate 3.6 % Dividend yield 0.01 % Expected volatility 26.2 % Expected term (in years) 6.2 Strike price (in dollars) $ 72
Summary of Share-Based Compensation Expense and Other Share-Based Compensation Data	Share-based Compensation Expense For the three months ended For the six months ended June 30, 2023 June 30, 2023 Share-based compensation expense (pre-tax) $ 28 $ 52 Income tax benefits (3) (11) Share-based compensation expense (after-tax) $ 25 $ 41 Other Share-based Compensation Data Unrecognized compensation expense as of June 30, 2023 (a) $ 202 Cash received from stock options exercised for the six months ended June 30, 2023 27 Intrinsic value of stock options exercised and RSU/PSUs vested in the six months ended June 30, 2023 57 (a) Amortized over a weighted average period of 2.2 years.

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings per Share	Earnings Per Share For the three months ended June 30 For the six months ended June 30 (In millions, except per share amounts) 2023 2022 2023 2022 Numerator: Net income from continuing operations $ 433 $ 486 $ 816 $ 888 Net (income) attributable to noncontrolling interests (15) (13) (26) (26) Net income from continuing operations attributable to GE HealthCare 418 473 790 862 Deemed preferred stock dividend of redeemable noncontrolling interest — — (183) — Net income from continuing operations attributable to GE HealthCare common shareholders 418 473 607 862 Income from discontinued operations, net of taxes — 12 — 12 Net income attributable to GE HealthCare common stockholders $ 418 $ 485 $ 607 $ 874 Denominator: Basic weighted-average shares outstanding 455 454 455 454 Dilutive effect of common stock equivalents 3 — 3 — Diluted weighted-average shares outstanding 458 454 458 454 Basic Earnings Per Share: Continuing operations $ 0.92 $ 1.04 $ 1.34 $ 1.90 Discontinued operations — 0.03 — 0.03 Attributable to GE HealthCare common stockholders 0.92 1.07 1.34 1.93 Diluted Earnings Per Share: Continuing operations $ 0.91 $ 1.04 $ 1.33 $ 1.90 Discontinued operations — 0.03 — 0.03 Attributable to GE HealthCare common stockholders 0.91 1.07 1.33 1.93 Antidilutive securities (a) 4 — 4 — (a) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORM_2

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Cash and Cash Equivalents	Cash, Cash Equivalents and Restricted Cash As of June 30, 2023 December 31, 2022 Cash and cash equivalents $ 1,936 $ 1,440 Short-term restricted cash 3 5 Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position 1,939 1,445 Long-term restricted cash (a) 6 6 Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows $ 1,945 $ 1,451 (a) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.
Schedule of Restricted Cash and Cash Equivalents	Cash, Cash Equivalents and Restricted Cash As of June 30, 2023 December 31, 2022 Cash and cash equivalents $ 1,936 $ 1,440 Short-term restricted cash 3 5 Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position 1,939 1,445 Long-term restricted cash (a) 6 6 Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows $ 1,945 $ 1,451 (a) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.
Schedule of Inventory	Inventories As of June 30, 2023 December 31, 2022 Raw materials $ 1,103 $ 1,053 Work in process 106 91 Finished goods 1,055 1,011 Inventories (a) $ 2,264 $ 2,155 (a) Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.
Summary of Property, Plant and Equipment	Property, Plant, and Equipment - Net As of June 30, 2023 December 31, 2022 Original cost $ 5,075 $ 4,989 Less accumulated depreciation and amortization (3,057) (2,988) Right-of-use operating lease assets 339 313 Property, plant, and equipment - net $ 2,357 $ 2,314
Schedule of Redeemable Noncontrolling Interest	The activity attributable to redeemable noncontrolling interests for the six months ended June 30, 2023 and 2022 is presented below. Redeemable Noncontrolling Interests For the six months ended June 30 2023 2022 Balance at beginning of period $ 230 $ 220 Net income attributable to redeemable noncontrolling interests 21 19 Redemption value adjustments (a) 183 — Distributions to and exercise of redeemable noncontrolling interests (b) (225) (19) Balance at end of period $ 209 $ 220 (a) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. These redeemable noncontrolling interests were remeasured to their current redemption value resulting in a redemption value adjustment of $183 million. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to retained earnings. (b) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023.
Schedule of Other Income (Expense)	Other Income (Expense) – Net For the three months ended June 30 For the six months ended June 30 2023 2022 2023 2022 Net interest and investment income (expense) $ — $ (10) $ 13 $ (12) Equity method investment income 5 6 9 9 Change in fair value of assumed obligation (6) — (19) — Other items, net (a) 15 23 19 48 Total other income (expense) – net $ 14 $ 19 $ 22 $ 45 (a) Other items, net primarily consists of lease income, licensing and royalty income, and gains and losses related to derivatives for the three and six months ended June 30, 2023, and licensing and royalty income, and gains and losses related to derivatives for the three and six months ended June 30, 2022.

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	Corporate Allocations from GE For the three months ended For the six months ended June 30, 2022 June 30, 2022 Costs for centralized services (a) $ 13 $ 26 Costs associated with employee medical insurance (b) 30 60 Costs for corporate and shared services (c) 104 220 (a) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Condensed Combined Statement of Income. (b) Costs associated with employee medical insurance were recognized within Cost of products, Cost of services, SG&A, and R&D in the Condensed Combined Statement of Income based on the employee population. (c) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Condensed Combined Statement of Income.

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended	6 Months Ended
	Jan. 03, 2023	Dec. 31, 2022	Jun. 30, 2023	Jun. 30, 2023
Subsidiary, Sale of Stock [Line Items]
Sale of stock, percent of stock distributed	80.10%
Sale of stock, number of shares issued	454,000,000	100
Sale of stock, price per share (in dollars per share)		$ 1
Net transfers from Parent, including Spin-Off-related adjustments, equity reduction	$ 2,840		$ 6	$ 2,840
Separation-related adjustments, deferred compensation liability	$ 548
GE
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued			29,000,000
GE | GE HealthCare Technologies Inc
Subsidiary, Sale of Stock [Line Items]
Ownership percentage			13.50%	13.50%

REVENUE RECOGNITION - Summary o

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Contract assets	$ 642	$ 584
Other deferred assets	402	405
Contract and other deferred assets	1,044	989
Non-current contract assets	54	37
Non-current other deferred assets	84	82
Total contract and other deferred assets	$ 1,182	$ 1,108

REVENUE RECOGNITION - Narrative

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	$ 2,673		$ 2,526
Contract liabilities, noncurrent	670		$ 630
Increase in contract liabilities, product growth, customer advances and deposits	147
Contract liabilities, revenue recognized	1,105	$ 1,083
Remaining performance obligation, amount	14,309
Products
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 4,992
Products | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	99%
Remaining performance obligation, period	2 years
Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 9,317
Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | Period one
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	67%
Remaining performance obligation, period	2 years
Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | Period two
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	97%
Remaining performance obligation, period	5 years

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 segment
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	4

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Revenue	$ 4,817	$ 4,484	$ 9,524	$ 8,827
Segment EBIT	711	719	1,375	1,318
Restructuring costs	(19)	(10)	(31)	(22)
Acquisition and disposition-related benefits (charges)	2	(14)	1	(29)
Gain/(loss) of business and asset dispositions	0	0	0	3
Spin-Off and separation costs	(72)	0	(130)	0
Amortization of acquisition-related intangible assets	(32)	(30)	(63)	(63)
Investment revaluation gain (loss)	(6)	(14)	(1)	(22)
Interest and other financial charges – net	(137)	(12)	(273)	(16)
Non-operating benefit (income) costs	123	1	238	3
Income from continuing operations before income taxes	570	639	1,116	1,172
Operating segments | Imaging
Segment Reporting Information [Line Items]
Revenue	2,620	2,449	5,116	4,760
Segment EBIT	278	306	469	512
Operating segments | Imaging | Radiology
Segment Reporting Information [Line Items]
Revenue	2,227	2,064	4,315	3,982
Operating segments | Imaging | Interventional Guidance
Segment Reporting Information [Line Items]
Revenue	393	385	801	778
Operating segments | Ultrasound
Segment Reporting Information [Line Items]
Revenue	839	828	1,698	1,643
Segment EBIT	191	220	398	412
Operating segments | PCS
Segment Reporting Information [Line Items]
Revenue	770	713	1,551	1,429
Segment EBIT	84	81	193	146
Operating segments | PCS | Monitoring Solutions
Segment Reporting Information [Line Items]
Revenue	563	512	1,115	1,033
Operating segments | PCS | Life Support Solutions
Segment Reporting Information [Line Items]
Revenue	207	201	436	396
Operating segments | PDx
Segment Reporting Information [Line Items]
Revenue	568	478	1,126	962
Segment EBIT	152	115	307	253
Other
Segment Reporting Information [Line Items]
Revenue	20	16	33	33
Segment EBIT	$ 6	$ (3)	$ 8	$ (5)

RECEIVABLES - Current Receivabl

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses	$ (92)	$ (91)
Chargebacks	140	157
Nonrelated party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current customer receivables	3,154	3,112
Non-income based tax receivables	196	174
Other sundry receivables	112	100
Sundry receivables	308	274
Allowance for credit losses	(92)	(91)
Total current receivables – net	$ 3,370	$ 3,295

RECEIVABLES - Long-Term Receiva

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Long-term customer receivables	$ 67	$ 80
Sundry receivables	76	57
Non-income based tax receivables	28	28
Supplier advances	11	11
Allowance for credit losses	(30)	(31)
Total long-term receivables – net	$ 152	$ 145

FINANCING RECEIVABLES - Schedul

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses, current	$ (4)	$ (4)
Current financing receivables, net	101	97
Allowance for credit losses, noncurrent	(5)	(6)
Non-current financing receivables, net	195	196
Loans, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	32	29
Non-current financing receivables, gross	43	44
Investment in financing leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	73	72
Non-current financing receivables, gross	$ 157	$ 158

FINANCING RECEIVABLES - Narrati

FINANCING RECEIVABLES - Narrative (Details)	Jun. 30, 2023	Dec. 31, 2022
Financing Receivable, Past Due [Line Items]
Financing receivable, nonaccrual, percent past due	5%	6%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	5%	7%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	4%	6%

LEASES (Details)

LEASES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Leases [Abstract]
Operating lease liability	$ 370		$ 370		$ 347
Operating lease expense	$ 57	$ 40	$ 113	$ 96

ACQUISITIONS, GOODWILL, AND O_3

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Feb. 17, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Consideration transferred, upfront payment				$ 147	$ 0
Contingent consideration		$ 65		65		$ 42
Goodwill		12,929		12,929		$ 12,813
Amortization of acquisition-related intangible assets		$ 93	$ 101	$ 189	$ 204
Caption Health
Business Acquisition [Line Items]
Percent of interest acquired	100%
Consideration transferred, upfront payment	$ 127
Consideration transferred, holdback payment	10
Contingent consideration	13
Goodwill	94
Intangible assets	60
Deferred tax liabilities	$ 3

ACQUISITIONS, GOODWILL, AND O_4

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 12,813
Acquisitions	110
Foreign exchange and other	6
Ending balance	12,929
Imaging
Goodwill [Roll Forward]
Beginning balance	4,409
Acquisitions	16
Foreign exchange and other	2
Ending balance	4,427
Ultrasound
Goodwill [Roll Forward]
Beginning balance	3,835
Acquisitions	94
Foreign exchange and other	1
Ending balance	3,930
PCS
Goodwill [Roll Forward]
Beginning balance	2,036
Acquisitions	0
Foreign exchange and other	2
Ending balance	2,038
PDx
Goodwill [Roll Forward]
Beginning balance	2,533
Acquisitions	0
Foreign exchange and other	1
Ending balance	$ 2,534

BORROWINGS - Narrative (Details

BORROWINGS - Narrative (Details)		6 Months Ended
	Jan. 03, 2023 USD ($)	Jun. 30, 2023 USD ($) series	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Weighted average interest rate		5.98%
Debt repayments		$ 0
Guarantor obligations, maximum exposure		114,000,000
Guarantee obligation, carrying value		4,000,000	$ 4,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		693,000,000	657,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		44,000,000	43,000,000
Senior notes | Senior unsecured notes
Debt Instrument [Line Items]
Debt, principal amount		$ 8,250,000,000
Number of debt series | series		6
Line of credit | Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding		$ 0	$ 0
Line of credit | Revolving credit facility | 5-Year Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term		5 years
Maximum borrowing capacity		$ 2,500,000,000
Line of credit | Revolving credit facility | 364-Day Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term		364 days
Maximum borrowing capacity		$ 1,000,000,000
Line of credit | Unsecured debt | Floating rate Term Loan Facility
Debt Instrument [Line Items]
Debt, term		3 years
Maximum borrowing capacity		$ 2,000,000,000
Proceeds from lines of credit	$ 2,000,000,000

BORROWINGS - Schedule of Long-T

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal debt issued	$ 10,282	$ 8,288
Less: Unamortized debt issuance costs and discounts	44	47
Less: Current portion of long-term borrowings	5	7
Long-term borrowings, net of current portion	$ 10,233	8,234
Senior notes | 5.550% senior notes due November 15, 2024
Debt Instrument [Line Items]
Stated interest rate	5.55%
Principal debt issued	$ 1,000	1,000
Senior notes | 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 1,500	1,500
Senior notes | 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750	1,750
Senior notes | 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250	1,250
Senior notes | 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750	1,750
Senior notes | 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000	1,000
Line of credit | Floating rate Term Loan Facility
Debt Instrument [Line Items]
Principal debt issued	2,000	0
Other
Debt Instrument [Line Items]
Principal debt issued	$ 32	$ 38

POSTRETIREMENT BENEFIT PLANS -

POSTRETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan liability					$ 0
Plan asset or obligation reporting threshold			$ 50,000,000	$ 20,000,000
Defined benefit plan, expected future employer contributions, current year	$ 353,000,000		353,000,000
Defined benefit plan, expected future employer contributions, plans no longer disclosed	11,000,000		11,000,000
Defined contribution plan, employer contribution amount	33,000,000	$ 35,000,000	66,000,000	66,000,000
Pension plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense	(85,000,000)	3,000,000	(165,000,000)	6,000,000
Defined benefit plan, employer contribution amount			107,000,000
Other postretirement plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense	$ (21,000,000)	0	(42,000,000)	0
Defined benefit plan, employer contribution amount			$ 73,000,000
U.S. GE Principal Pension and Principal Retiree Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense		25,000,000		49,000,000
Non-U.S. GE Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense		$ 12,000,000		$ 16,000,000

POSTRETIREMENT BENEFIT PLANS _2

POSTRETIREMENT BENEFIT PLANS - Schedule of Defined Benefit Plans (Details) $ in Millions	Jan. 01, 2023 USD ($)
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	$ 22,906
Unrecognized gain to be recorded in AOCI	2,481
Net Benefit Liability
Projected benefit obligations	22,953
Fair value of assets	18,908
Net liability	4,045
Defined benefit plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	21,696
Unrecognized gain to be recorded in AOCI	1,258
Net Benefit Liability
Projected benefit obligations	21,743
Fair value of assets	18,908
Net liability	2,835
Other postretirement plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	1,210
Unrecognized gain to be recorded in AOCI	1,223
Net Benefit Liability
Projected benefit obligations	1,210
Fair value of assets	0
Net liability	$ 1,210

POSTRETIREMENT BENEFIT PLANS _3

POSTRETIREMENT BENEFIT PLANS - Components of Net Periodic Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Non-operating	$ (123)	$ (1)	$ (238)	$ (3)
Defined benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	15	5	29	10
Interest cost	290	5	582	9
Expected return on plan assets	(357)	(7)	(713)	(14)
Amortization of net loss (gain)	(32)	1	(61)	3
Amortization of prior service cost (credit)	(1)	(1)	(2)	(2)
Non-operating	(100)	(2)	(194)	(4)
Net periodic expense (income)	(85)	3	(165)	6
Other postretirement plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	2	0	4	0
Interest cost	15	0	30	0
Expected return on plan assets	0	0	0	0
Amortization of net loss (gain)	(16)	0	(32)	0
Amortization of prior service cost (credit)	(22)	0	(44)	0
Non-operating	(23)	0	(46)	0
Net periodic expense (income)	$ (21)	$ 0	$ (42)	$ 0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023	Jan. 03, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	24%	23.90%	26.90%	24.20%
Deferred tax liabilities, undistributed foreign earnings					$ 30
Deferred tax assets, net						$ 3,099
Deferred tax assets, pension and post retirement benefits						$ 964

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	$ 6,696	$ 16,578	$ 9,362	$ 16,676
Other comprehensive income (loss) before reclass – net of taxes	44	(472)	103	(595)
Unrecognized gain transferred from GE pension – net of taxes			1,972
Reclass from AOCI – net of taxes	(49)	(6)	(127)	(17)
Equity, ending balance	7,114	17,054	7,114	17,054
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	75	(1,171)	(1,878)	(1,037)
Equity, ending balance	70	(1,649)	70	(1,649)
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(1,760)	(1,122)	(1,845)	(969)
Other comprehensive income (loss) before reclass – net of taxes	3	(472)	88	(625)
Unrecognized gain transferred from GE pension – net of taxes			0
Reclass from AOCI – net of taxes	0	0	0	0
Equity, ending balance	(1,757)	(1,594)	(1,757)	(1,594)
Other comprehensive income (loss) before reclass, tax	28	(12)	17	(14)
Unrecognized gain transferred from GE pension, tax			0
Reclass from AOCI, tax	0	0	0	0
Other comprehensive income (loss) before reclass, tax, spin-off related adjustments				28
Benefit plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	1,865	(105)	(42)	(100)
Other comprehensive income (loss) before reclass – net of taxes	36	3	23	(2)
Unrecognized gain transferred from GE pension – net of taxes			1,972
Reclass from AOCI – net of taxes	(54)	0	(106)	0
Equity, ending balance	1,847	(102)	1,847	(102)
Other comprehensive income (loss) before reclass, tax	(11)	(1)	(9)	(10)
Unrecognized gain transferred from GE pension, tax			(509)
Reclass from AOCI, tax	17	0	33	0
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(30)	56	9	32
Other comprehensive income (loss) before reclass – net of taxes	5	(3)	(8)	32
Unrecognized gain transferred from GE pension – net of taxes			0
Reclass from AOCI – net of taxes	5	(6)	(21)	(17)
Equity, ending balance	(20)	47	(20)	47
Other comprehensive income (loss) before reclass, tax	(2)	4	2	(2)
Unrecognized gain transferred from GE pension, tax			0
Reclass from AOCI, tax	$ (1)	$ 0	$ 6	$ 0

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Derivative [Line Items]
AOCI, cash flow hedge cumulative net gain (loss)	$ (20)		$ (20)
Cash flow hedge gain to be reclassified within 12 months			14
Cash flow hedges, pre-tax gains (losses) reclassified from AOCI into earnings	(6)	$ 6	$ 27	$ 17
Maximum length of time hedged in cash flow hedge			2 years
Notional amount	9,729		$ 9,729		$ 8,488
Derivative, potential effect of rights of offset to assets and liabilities	64		64
Equity investments without readily determinable fair value	121		121		117
Estimated fair value
Derivative [Line Items]
Long-term debt	10,630		10,630		8,512
Carrying value
Derivative [Line Items]
Long-term debt	10,238		10,238		8,241
Net investment hedges | Designated as hedging instrument
Derivative [Line Items]
Notional amount	$ 2,296		$ 2,296		$ 2,132

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Derivative [Line Items]
Gross Notional	$ 9,729	$ 8,488
Fair Value – Assets	152	66
Fair Value – Liabilities	312	209
Designated as hedging instrument | Cash flow hedges
Derivative [Line Items]
Gross Notional	1,206	1,240
Fair Value – Assets	34	32
Fair Value – Liabilities	56	53
Designated as hedging instrument | Cash flow hedges | Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	1,206	1,240
Fair Value – Assets	34	32
Fair Value – Liabilities	56	53
Designated as hedging instrument | Net investment hedges
Derivative [Line Items]
Gross Notional	2,296	2,132
Fair Value – Assets	32	0
Fair Value – Liabilities	213	111
Designated as hedging instrument | Net investment hedges | Cross-currency swaps
Derivative [Line Items]
Gross Notional	2,197	2,132
Fair Value – Assets	29	0
Fair Value – Liabilities	211	111
Designated as hedging instrument | Net investment hedges | Foreign currency exchange contracts and options
Derivative [Line Items]
Gross Notional	99	0
Fair Value – Assets	3	0
Fair Value – Liabilities	2	0
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	6,227	5,116
Fair Value – Assets	86	34
Fair Value – Liabilities	43	45
Not designated as hedging instrument | Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	5,269	4,456
Fair Value – Assets	34	9
Fair Value – Liabilities	24	20
Not designated as hedging instrument | Embedded derivatives
Derivative [Line Items]
Gross Notional	683	604
Fair Value – Assets	20	24
Fair Value – Liabilities	13	18
Not designated as hedging instrument | Equity contracts
Derivative [Line Items]
Gross Notional	198	8
Fair Value – Assets	31	0
Fair Value – Liabilities	3	6
Not designated as hedging instrument | Commodity derivatives
Derivative [Line Items]
Gross Notional	77	48
Fair Value – Assets	1	1
Fair Value – Liabilities	$ 3	$ 1

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Cash flow hedges	$ 7	$ (7)	$ (10)	$ 34
Net investment hedges	$ (36)	$ 0	$ (71)	$ 0

FINANCIAL INSTRUMENTS AND FAI_6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Effect of Derivatives Instruments on Statements of Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	$ (6)	$ 6	$ 27	$ 17
Selling, general and administrative
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedges	18	0	33	0
Selling, general and administrative | Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedges	0	0	0	0
Selling, general and administrative | Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	0	0	0
Selling, general and administrative | Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	18	0	33	0
Selling, general and administrative | Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	0	0	0
Other
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedges	4	16	5	29
Other | Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedges	4	7	5	7
Other | Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	2	5	1	8
Other | Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	(1)	3	(1)
Other | Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	(2)	5	(4)	15
Products | Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(5)	5	22	14
Effects of derivatives not designated as hedges	3	(60)	10	(61)
Products | Cost of revenue | Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(5)	5	22	14
Effects of derivatives not designated as hedges	3	(60)	10	(61)
Products | Cost of revenue | Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	0	0	0
Products | Cost of revenue | Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	0	0	0
Products | Cost of revenue | Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	0	0	0
Services | Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	1	5	3
Effects of derivatives not designated as hedges	1	(11)	3	(11)
Services | Cost of revenue | Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	1	5	3
Effects of derivatives not designated as hedges	1	(11)	3	(11)
Services | Cost of revenue | Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	0	0	0
Services | Cost of revenue | Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	0	0	0	0
Services | Cost of revenue | Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedges	$ 0	$ 0	$ 0	$ 0

FINANCIAL INSTRUMENTS AND FAI_7

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Assets:
Investment securities	$ 30	$ 21
Derivatives	152	66
Liabilities:
Deferred compensation	246	64
Derivatives	312	209
Contingent consideration	65	42
Level 1
Assets:
Investment securities	30	21
Derivatives	0	0
Liabilities:
Deferred compensation	243	62
Derivatives	0	0
Contingent consideration	0	0
Level 2
Assets:
Investment securities	0	0
Derivatives	152	66
Liabilities:
Deferred compensation	3	2
Derivatives	309	203
Contingent consideration	0	0
Level 3
Assets:
Investment securities	0	0
Derivatives	0	0
Liabilities:
Deferred compensation	0	0
Derivatives	3	6
Contingent consideration	$ 65	$ 42

COMMITMENTS, GUARANTEES, PROD_3

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Narrative (Details) $ in Millions	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, maximum exposure	$ 114

COMMITMENTS, GUARANTEES, PROD_4

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Product Warranties (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 193	$ 161
Current-year provisions	102	131
Expenditures	(105)	(104)
Other changes	0	(5)
Balance at end of period	$ 190	$ 183

RESTRUCTURING AND OTHER ACTIV_3

RESTRUCTURING AND OTHER ACTIVITIES - NET - Narrative (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Jan. 03, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring expenses, net		$ 19	$ 10	$ 31	$ 22
Expected additional restructuring expense		35		35
Accrual adjustment	$ 31
Restructuring liabilities		$ 91		$ 91		$ 75

RESTRUCTURING AND OTHER ACTIV_4

RESTRUCTURING AND OTHER ACTIVITIES - NET - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 15	$ 9	$ 25	$ 18
Facility and other exit costs	0	1	1	4
Asset write-downs	4	0	5	0
Total restructuring and other activities – net	$ 19	$ 10	$ 31	$ 22

SHARE-BASED COMPENSATION - Narr

SHARE-BASED COMPENSATION - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance	41,000
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period	10 years
Stock options | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Stock options | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months
Performance Shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Units outstanding (in shares)	1,293
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 85
Intrinsic value, outstanding | $	$ 105
Weighted average remaining contractual term, outstanding	1 year 9 months 18 days

SHARE-BASED COMPENSATION - Summ

SHARE-BASED COMPENSATION - Summary of Weighted Average Grant Date Fair Value (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options (in dollars per share)	$ 25
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	73	$ 73
PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 84

SHARE-BASED COMPENSATION - Sche

SHARE-BASED COMPENSATION - Schedule of Stock Options Valuation Assumptions (Details) - Stock options	6 Months Ended
	Jun. 30, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free rate	3.60%
Dividend yield	0.01%
Expected volatility	26.20%
Expected term (in years)	6 years 2 months 12 days
Strike price (in dollars per share)	$ 72

SHARE-BASED COMPENSATION - Su_2

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares
Stock options, shares
Outstanding at beginning of period (in shares) | shares		3,738
Granted (in shares) | shares		2,143
Exercised (in shares) | shares		(448)
Forfeited (in shares) | shares		(31)
Expired (in shares) | shares		(30)
Outstanding at end of period (in shares) | shares	5,372	5,372
Exercisable (in shares) | shares	3,044	3,044
Expected to vest (in shares) | shares	1,780	1,780
Stock options, weighted average exercise price
Outstanding at beginning of period (in dollars per share) | $ / shares		$ 90
Granted (in dollars per share) | $ / shares		72
Exercised (in dollars per share) | $ / shares		60
Forfeited (in dollars per share) | $ / shares		69
Expired (in dollars per share) | $ / shares		131
Outstanding at end of period (in dollars per share) | $ / shares	$ 85	85
Exercisable (in dollars per share) | $ / shares	95	95
Expected to vest (in dollars per share) | $ / shares	$ 72	$ 72
Stock options, weighted average contractual term (in years)
Stock options, weighted average remaining contractual term, outstanding		6 years 4 months 24 days
Stock options, weighted average remaining contractual term, exercisable		4 years
Stock options, weighted average remaining contractual term, expected to vest		9 years 6 months
Stock options, intrinsic value
Stock options, intrinsic value, outstanding | $	$ 53	$ 53
Stock options, intrinsic value, exercisable | $	31	31
Stock options, intrinsic value, expected to vest | $	$ 17	$ 17
RSUs
RSUs, shares
Outstanding at beginning of period (in shares) | shares		3,551
Granted (in shares) | shares		1,788
Vested (in shares) | shares		(672)
Forfeited (in shares) | shares		(158)
Outstanding at end of period (in shares) | shares	4,509	4,509
Expected to vest (in shares) | shares	3,851	3,851
RSUs, weighted average grant date fair value
Outstanding at beginning of period (in dollars per share) | $ / shares		$ 58
Granted (in dollars per share) | $ / shares	$ 73	73
Vested (in dollars per share) | $ / shares		70
Forfeited (in dollars per share) | $ / shares		62
Outstanding at end of period (in dollars per share) | $ / shares	63	63
Expected to vest (in dollars per share) | $ / shares	$ 55	$ 55
RSUs, weighted average contractual term (in years)
Weighted average remaining contractual term, outstanding		1 year 9 months 18 days
Weighted average remaining contractual term, expected to vest		1 year 9 months 18 days
RSUs, intrinsic value
Intrinsic value, outstanding | $	$ 368	$ 368
Intrinsic value, expected to vest | $	$ 313	$ 313

SHARE-BASED COMPENSATION - Su_3

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based compensation expense (pre-tax)	$ 28	$ 52
Income tax benefits	(3)	(11)
Share-based compensation expense (after-tax)	$ 25	$ 41

SHARE-BASED COMPENSATION - Su_4

SHARE-BASED COMPENSATION - Summary of Other Share-Based Compensation Data (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Unrecognized compensation expense as of June 30, 2023	$ 202
Cash received from stock options exercised for the six months ended June 30, 2023	27
Intrinsic value of stock options exercised and RSU/PSUs vested in the six months ended June 30, 2023	$ 57
Weighted average period of recognition	2 years 2 months 12 days

EARNINGS PER SHARE - Narrative

EARNINGS PER SHARE - Narrative (Details) - shares	Jun. 30, 2023	Jan. 03, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Common stock, outstanding (in shares)	454,808,732	454,000,000	100

EARNINGS PER SHARE - Schedule o

EARNINGS PER SHARE - Schedule of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net income from continuing operations	$ 433	$ 486	$ 816	$ 888
Net (income) attributable to noncontrolling interests	(15)	(13)	(26)	(26)
Net income from continuing operations attributable to GE HealthCare	418	473	790	862
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	(183)	0
Net income from continuing operations attributable to GE HealthCare common shareholders	418	473	607	862
Income from discontinued operations, net of taxes	0	12	0	12
Net income attributable to GE HealthCare common stockholders	$ 418	$ 485	$ 607	$ 874
Denominator:
Basic weighted-average shares outstanding	455	454	455	454
Dilutive effect of common stock equivalents (in shares)	3	0	3	0
Diluted weighted-average shares outstanding	458	454	458	454
Basic Earnings Per Share:
Continuing operations (in dollars per share)	$ 0.92	$ 1.04	$ 1.34	$ 1.90
Discontinued operations (in dollars per share)	0	0.03	0	0.03
Attributable to GE HealthCare common stockholders (in dollars per share)	0.92	1.07	1.34	1.93
Diluted Earnings Per Share:
Continuing operations (in dollars per share)	0.91	1.04	1.33	1.90
Discontinued operations (in dollars per share)	0	0.03	0	0.03
Attributable to GE HealthCare common stockholders (in dollars per share)	$ 0.91	$ 1.07	$ 1.33	$ 1.93
Antidilutive securities (in shares)	4	0	4	0

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 1,936	$ 1,440
Short-term restricted cash	3	5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	1,939	1,445
Long-term restricted cash	6	6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$ 1,945	$ 1,451	$ 530	$ 561

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,103	$ 1,053
Work in process	106	91
Finished goods	1,055	1,011
Inventories	$ 2,264	$ 2,155

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Original cost	$ 5,075	$ 4,989
Less accumulated depreciation and amortization	(3,057)	(2,988)
Right-of-use operating lease assets	339	313
Property, plant, and equipment - net	$ 2,357	$ 2,314

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Supplier Finance Program [Line Items]
Supplier finance program, payment terms, maximum threshold	180 days
Supplier finance program obligation	$ 422	$ 392
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	150 days

SUPPLEMENTAL FINANCIAL INFORM_7

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
	Jan. 03, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period			$ 230	$ 220
Net income attributable to redeemable noncontrolling interests			21	19
Redemption value adjustments	$ 183		183	0
Distributions to and exercise of redeemable noncontrolling interests			(225)	(19)
Balance at end of period		$ 209	209	220
Noncontrolling interest redemption payment		$ 211	$ 211	$ 0

SUPPLEMENTAL FINANCIAL INFORM_8

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net interest and investment income (expense)	$ 0	$ (10)	$ 13	$ (12)
Equity method investment income	5	6	9	9
Change in fair value of assumed obligation	(6)	0	(19)	0
Other items, net	15	23	19	48
Total other income (expense) – net	$ 14	$ 19	$ 22	$ 45

RELATED PARTIES - Narrative (De

RELATED PARTIES - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) director	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Related Party Transaction [Line Items]
All other assets	$ 2,013		$ 2,013		$ 1,024
All other liabilities	1,926		1,926		$ 1,603
Revenue	4,817	$ 4,484	9,524	$ 8,827
Majority shareholder | Separation costs related to pension, benefit and contribution plans
Related Party Transaction [Line Items]
Transaction amount		64		123
Majority shareholder | Share-based compensation expense
Related Party Transaction [Line Items]
Transaction amount		$ 20		$ 39
Related party
Related Party Transaction [Line Items]
All other assets	88		88
All other liabilities	132		132
Related party | Transition Services Agreement
Related Party Transaction [Line Items]
Transaction amount	84		$ 192
Agreement term			36 months
Related party | Tax Matters Agreement
Related Party Transaction [Line Items]
Period following distribution date			2 years
Directors
Related Party Transaction [Line Items]
Number of board members | director			2
Revenue	$ 23		$ 47

RELATED PARTIES - Schedule of R

RELATED PARTIES - Schedule of Related Party Transactions (Details) - Majority shareholder - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Costs for centralized services
Related Party Transaction [Line Items]
Transaction amount	$ 13	$ 26
Costs associated with employee medical insurance
Related Party Transaction [Line Items]
Transaction amount	30	60
Costs for corporate and shared services
Related Party Transaction [Line Items]
Transaction amount	$ 104	$ 220